PL3191120T3 - Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów - Google Patents

Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów

Info

Publication number
PL3191120T3
PL3191120T3 PL15767597.6T PL15767597T PL3191120T3 PL 3191120 T3 PL3191120 T3 PL 3191120T3 PL 15767597 T PL15767597 T PL 15767597T PL 3191120 T3 PL3191120 T3 PL 3191120T3
Authority
PL
Poland
Prior art keywords
antagonists
progression
inhibit
psoriatic arthritis
structural damage
Prior art date
Application number
PL15767597.6T
Other languages
English (en)
Polish (pl)
Inventor
Shephard Mpofu
Hanno Richards
Gregory LIGOZIO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3191120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3191120T3 publication Critical patent/PL3191120T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
PL15767597.6T 2014-09-10 2015-09-08 Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów PL3191120T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
PL3191120T3 true PL3191120T3 (pl) 2024-08-26

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15767597.6T PL3191120T3 (pl) 2014-09-10 2015-09-08 Zastosowanie antagonistów il-17 do hamowania postępu uszkodzeń strukturalnych u pacjentów z łuszczycowym zapaleniem stawów

Country Status (22)

Country Link
US (2) US11278618B2 (cg-RX-API-DMAC7.html)
EP (2) EP4406969A3 (cg-RX-API-DMAC7.html)
JP (4) JP2017528465A (cg-RX-API-DMAC7.html)
KR (2) KR20170045240A (cg-RX-API-DMAC7.html)
CN (4) CN113069542A (cg-RX-API-DMAC7.html)
AU (2) AU2015313827C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017003332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3191120T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981697T3 (cg-RX-API-DMAC7.html)
FI (1) FI3191120T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240921T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067081T2 (cg-RX-API-DMAC7.html)
LT (1) LT3191120T (cg-RX-API-DMAC7.html)
MX (1) MX2017003216A (cg-RX-API-DMAC7.html)
PL (1) PL3191120T3 (cg-RX-API-DMAC7.html)
PT (1) PT3191120T (cg-RX-API-DMAC7.html)
RS (1) RS65851B1 (cg-RX-API-DMAC7.html)
RU (1) RU2697383C2 (cg-RX-API-DMAC7.html)
SI (1) SI3191120T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400285T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016038538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3191120T3 (da) * 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt
RU2754683C2 (ru) 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
US20210179702A1 (en) * 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
MX2021014953A (es) * 2019-06-04 2022-01-24 Janssen Biotech Inc Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23.
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP1963368B3 (en) 2005-12-13 2020-06-10 Eli Lilly And Company Anti-il-17 antibodies
CN101374864A (zh) 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100239590A1 (en) 2007-06-20 2010-09-23 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
WO2010034443A1 (en) 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Antibodies against human il 17 and uses thereof
LT2625199T (lt) * 2010-10-08 2018-03-12 Novartis Ag Psoriazės gydymo būdai panaudojant il-17 antagonistus
CN104800844A (zh) * 2010-11-05 2015-07-29 诺华有限公司 使用il-17拮抗剂治疗类风湿性关节炎的方法
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
US20150064193A1 (en) * 2011-11-21 2015-03-05 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
DK3191120T3 (da) * 2014-09-10 2024-07-15 Novartis Ag Anvendelse af IL-17-antagonister for at hæmme progressionen af strukturel skade hos patienter med psoriasisgigt

Also Published As

Publication number Publication date
FI3191120T3 (fi) 2024-07-10
KR20170045240A (ko) 2017-04-26
KR20230170796A (ko) 2023-12-19
RU2017107501A (ru) 2018-10-10
SMT202400285T1 (it) 2024-09-16
JP2025024104A (ja) 2025-02-19
RU2697383C2 (ru) 2019-08-13
EP4406969A3 (en) 2024-11-27
US11278618B2 (en) 2022-03-22
CN107073110A (zh) 2017-08-18
CA2960754A1 (en) 2016-03-17
AU2015313827A1 (en) 2017-02-16
JP2021152021A (ja) 2021-09-30
JP2017528465A (ja) 2017-09-28
CN113069542A (zh) 2021-07-06
MX2017003216A (es) 2017-05-23
CN115957326A (zh) 2023-04-14
EP3191120A1 (en) 2017-07-19
AU2018201410A1 (en) 2018-03-22
JP2023109973A (ja) 2023-08-08
SI3191120T1 (sl) 2024-10-30
RU2017107501A3 (cg-RX-API-DMAC7.html) 2019-03-12
JP7591092B2 (ja) 2024-11-27
AU2015313827B2 (en) 2018-02-15
US20220313818A1 (en) 2022-10-06
HRP20240921T1 (hr) 2024-10-11
US20170281762A1 (en) 2017-10-05
AU2015313827C1 (en) 2018-08-30
DK3191120T3 (da) 2024-07-15
PT3191120T (pt) 2024-07-16
ES2981697T3 (es) 2024-10-10
BR112017003332A2 (pt) 2017-11-28
LT3191120T (lt) 2024-07-25
WO2016038538A1 (en) 2016-03-17
JP7288927B2 (ja) 2023-06-08
RS65851B1 (sr) 2024-09-30
EP4406969A2 (en) 2024-07-31
HUE067081T2 (hu) 2024-09-28
CN115944734A (zh) 2023-04-11
EP3191120B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
IL280905A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
SMT202400285T1 (it) Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
GB201416102D0 (en) Impovements In or Relating To Shower Rods
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL251904B (en) Epilimod for use in the treatment of melanoma
GB201702982D0 (en) Improvements in or relating to centralisers
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL237705B (en) Placement of electrodes near the heart
PL3137622T3 (pl) Sposoby redukowania spadku pojemności życiowej
GB201705271D0 (en) Technology to facilitate and promote the use of environmentally-friendly transport
ZA201702488B (en) Improvements in or relating to connecting devices
PT2965765T (pt) Utilização de adelmidrol no tratmento de disfunções epiteliais
GB201416463D0 (en) Improvements in or relating to temporary structures
GB2545716B (en) Improvements in or relating to the separation of radon
GB201419593D0 (en) Improvements in or relating to connecting devices
UA28633S (uk) Кутова оздоба до пам'ятника намогильного
ZA201408464B (en) Composition for the use in treatment of asthma
GB201415704D0 (en) Improvements in or Relating to Storage
GB201415702D0 (en) Improvements in or relating to storage
GB201415705D0 (en) Improvements in or Relating to Storage
GB201404391D0 (en) Novel compositions having use in therapy
GB201406072D0 (en) Improvements in or relating to storage
GB201406078D0 (en) Improvements in or relating to storage
GB201412345D0 (en) Improvements in and relating to devices